PSX-514
/ PharmassêtX
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 18, 2024
PharmassêtX Files Patent Application on New Form of Drug Substance from Green Tea
(PRNewswire)
- "PharmassêtX Inc...announced that the US Patent and Trademark Office has acknowledged receipt of the Company's patent application entitled 'CRYSTALLINE FORM OF EPIGALLOCATECHIN-3-GALLATE.' PharmassêtX is developing the novel form of epigallocatechin gallate (EGCG) as a prescription drug for the treatment of inflammatory bowel disease (IBD)....The patent-pending EGCG polymorph (solid-state form), under development by PharmassêtX as PSX-514, is initially targeted as a treatment for pouchitis, a rare IBD condition experienced by certain patients who have undergone surgery to remove their large intestine."
Patent • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 1
Of
1
Go to page
1